Related Experiment Video
Updated: Nov 12, 2025

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
Published on: March 26, 2018
The current diagnosis and treatment of patients with aortic valve stenosis
1University of South Florida, Tampa, FL 33612, USA.
Insights
Aortic valve stenosis (AS) is a common heart condition. Severe AS, indicated by specific measurements, requires timely intervention, with valve replacement or transcatheter aortic valve implantation as key treatments.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Valvular Heart Disease
Background:
- Aortic valve stenosis (AS) is a prevalent cardiovascular disease, often caused by bicuspid aortic valves or calcific degeneration.
- Symptomatic severe AS significantly increases mortality risk, escalating from 1% annually to 2% monthly.
Purpose of the Study:
- To discuss the staging and management strategies for aortic valve stenosis.
- To review current treatment options, including surgical valve replacement and transcatheter aortic valve implantation.
Main Methods:
- Diagnosis of severe AS based on echocardiographic parameters (valve area, velocity, gradient) and CT calcium scores.
- Assessment of surgical risk using EuroSCORE and STS Predicted Risk of Mortality.
- Evaluation of transcatheter aortic valve implantation (TAVI) as an alternative treatment.
Main Results:
- Severe AS is defined by specific echocardiographic and CT criteria.
- High surgical risk (EuroSCORE ≥20%, STS ≥8%) and comorbidities influence treatment decisions.
- TAVI offers an alternative for patients across all surgical risk categories.
Conclusions:
- Management of AS involves careful consideration of patient risk, valve characteristics, and patient preference.
- Surgical valve replacement is recommended for low-to-intermediate risk patients.
- TAVI is a viable option for older patients or those at high/prohibitive surgical risk.
Abstract:
Aortic valve stenosis (AS) is the third most frequent cardiovascular abnormality after coronary artery disease and hypertension. A bicuspid aortic valve is the most common cause for AS until seventh decade and calcific valve degeneration is responsible thereafter. In symptomatic patients, The risk of death increases from ≤1%/year to 2%/month. An echo valve area ≤1 cm2, peak transaortic velocity ≥4 m/s, mean valve gradient ≥40 mmHg and/or computerized tomography valve calcium score >2000 Agatston units (AU) for males or more than 1200 AU for females indicate severe AS. AS stages and management are discussed. Valve replacement is based on surgical risk, valve durability/hemodynamics, need for anticoagulation and patient preferences. EuroSCORE ≥20%, Society of Thoracic Surgeons Predicted Risk of Mortality ≥8% and co-morbidities indicate high surgical risk. Surgery is recommended for low-intermediate risk patients. Transcatheter aortic valve implantation is an alternative in older patients at low, intermediate, high or prohibitive risk. Transaortic valve implantation/replacement trials are summarized.
More Related Videos
12:17Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
06:51Author Spotlight: Development of a Minimally Invasive Large-Animal Model for Reliable and Reproducible Cardiovascular Research
Published on: October 20, 2023
Related Concept Videos
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Stenosis IV: Nursing Management
Aortic Regurgitation IV: Nursing Management
Mitral Stenosis II: Clinical features and Diagnostic Tests
Aortic Regurgitation I: Introduction